| Name | Title | Contact Details |
|---|---|---|
Hannah Hughes |
VP of Marketing | Profile |
Model No. was founded to rethink and elevate our experience in the spaces we design and inhabit. We design and make furnishings that harmonize with the space, lift the human experience, and eliminate our impact on the environment. Our collaborators - architects and design professionals - see the problem: Building and the turnover of commercial interiors generate well-over a third of the worlds CO2 emissions and an endless stream of waste. With these mission-driven partners, we create spaces we want without the waste. Circular at our core, Model No. achieves this through elevated design, regenerative and biodegradable materials, and 3D manufacturing. Starting a project with us begins with an email: info@model-no.com
With a history of over 25 years, Ceto has forged enduring partnerships with over 2,000 regional and community banks and credit unions nationwide, igniting their profitability and growth. Our unwavering commitment lies in empowering financial institutions with cutting-edge intelligence and transformative solutions, elevating shareholder value, and fostering thriving, prosperous communities. Discover more at ceto.com or dial 866.227.1361 to embark on a transformative journey.
Flynn Restaurant operates franchise over 1200 restaurants in the U.S. under the Applebees, Arbys, Panera and Taco Bell Brands.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.